Syncom Formulations India Ltd

Kedarmal Bankda – WTD resignation

• Kedarmal Shankarlal Bankda resigns as Whole-time Director, effective Aug 11, 2026; reason: pursue health and succession planning.

Vijay Bankda – MD resignation

• Vijay Shankarlal Bankda resigns as Managing Director, effective Aug 11, 2026; reason: leadership transition and succession.

Rahul Bankda – CFO resignation

• Rahul Vijay Bankda resigns as CFO (Senior Management), effective Aug 11, 2026; reason: pursuing other professional responsibilities.

Rinki Ankit Bankda – WTD appointment

• Rinki Ankit Bankda appointed Additional Director and Whole Time Director, effective Aug 12, 2026, subject to AGM approval.
• Relationship: Spouse of Ankit Kedarmal Bankda, current Chairman and Whole-Time Director.

Rahul Vijay Bankda – Additional Director & MD appointment

• Rahul Vijay Bankda appointed Additional Director and Managing Director, effective Aug 12, 2026, subject to AGM approval.
• Relationship: He is the son of Vijay Shankarlal Bankda.

Ankur Vijay Bankda – CFO designation

• Ankur Vijay Bankda redesignated as Chief Financial Officer (Senior Management), effective Aug 12, 2026.
• Relationship: He is the son of Vijay Shankarlal Bankda.

Ruchi Jindal – Woman Independent Director reappointment

• Ruchi Jindal reappointed as Woman Independent Director, effective June 29, 2027; subject to AGM approval.

E-voting details

• E-voting platform provided by CDSL.
• Cut-off date for e-voting entitlement is 23 September 2026.
• Voting starts 27 September 2026 at 9:00 A.M.
• Voting ends 29 September 2026 at 5:00 P.M.
• Scrutinizer: CS Anish Gupta, Practicing Company Secretary.
• AGM to be held on 30 September 2026 at 2:00 PM.

Auditor appointments FY2026-27

• Board approved appointment of M/s M. Goyal & Co. Cost Accountants as Cost Auditor for FY 2026-27.
• Date of appointment: 12 August 2026; Firm Reg. No. 000051.
• Appointment based on Audit Committee recommendation and Board approval.
• Board approved appointment of M/s Bansal & Agrawal as Internal Auditor for FY 2026-27.
• Date of appointment: 12 August 2026; Firm Reg. No. 010803C.

Standalone results

• Standalone Q1 FY27 revenue from operations: Rs 12,465.95 lakhs; total income: Rs 13,247.75 lakhs.
• Profit after tax: Rs 2,458.92 lakhs; restated EPS (PAT) 0.26.
• Total comprehensive income: Rs 2,840.79 lakhs; PBT before tax: Rs 3,190.88 lakhs.
• Earnings per share (continuing operations): Basic 0.26; Diluted 0.26.

Consolidated results

• Consolidated Q1 FY27 revenue from operations: Rs 12,552.64 lakhs; total income: Rs 13,335.58 lakhs.
• Profit after tax from continuing operations: Rs 2,484.68 lakhs; total comprehensive income: Rs 2,866.55 lakhs.
• Earnings per share (consolidated): Basic 0.26; Diluted 0.26; restated PAT EPS 0.26.
• Board approved results on 11 August 2026; limited review completed.

Segment and notes

• Standalone segment revenue: Pharma & Formulations Rs 13,135.70 lakhs; Trading Rs 27.84; Renting Rs 84.13.
• Total standalone segment revenue: Rs 13,247.71 lakhs.
• Three wholly owned subsidiaries: Synmex Pharma Pvt Ltd, Vincit Pharma Pvt Ltd, Sante Biotech Pvt Ltd.
• EPS restatement due to IND AS 33; comparative EPS restated.

Dividend details

• Final dividend of Rs 0.10 per equity share (face value Rs 1).
• Record date fixed at 23 September 2026 for dividend entitlement.
• Dividend rate is 10% of face value for FY 2025-26.
• Subject to approval by shareholders at the 38th AGM on 30 Sept 2026.
• Equity shares eligible for the final dividend.

Financial results and reports

• Unaudited standalone and consolidated quarterly results for quarter ended 30 June 2026 approved.
• Limited Review Report on standalone and consolidated results for quarter ended 30 June 2026 taken on record.

AGM preparations and disclosures

• Approval of Board Report and AGM Notice for 38th AGM on 30 Sep 2026 via VC/OAVM.
• Finalisation of annual book closure for the 38th AGM.
• Finalisation of cut-off date for eligibility for Remote E-voting and E-voting at AGM.
• Scrutinizer appointed for remote E-voting and AGM E-voting.
• Record date 23 Sep 2026 for final dividend, subject to AGM approval.
• Annexure 1 provides record date details.

Capital and governance actions

• Appointment of Cost Auditor with remuneration subject to shareholder ratification at AGM.
• Appointment of Internal Auditor.
• Reappointment of Woman Independent Director Smt. Ruchi Jindal subject to AGM approval.

Resignations

• Noted resignations of Whole-Time Director Kedarmal Shankarlal Bankda, MD Vijay Shankarlal Bankda, CFO Rahul Vijay Bankda.

New appointments

• Appointed Mrs. Rinki Ankit Bankda as Additional Director and Whole-Time Director, effective 12 Aug 2026, subject to approval.
• Appointed Shri Rahul Vijay Bankda as Additional Director and MD, effective 12 Aug 2026, subject to approval.
• Appointed Shri Ankur Vijay Bankda as CFO, effective 12 Aug 2026.

Dividend and approvals

• Final dividend of Re 0.10 per share, subject to shareholders' approval at AGM.

Resignation details

• Vijay Shankarlal Bankda resigns as Managing Director and Director, effective 11 August 2026.
• Reason: leadership transition and succession planning to ensure stability and smooth handover.

Dematerialisation processing confirmations

• RTA processed dematerialisation requests during quarter ended 30 June 2026 and confirmed outcomes to depositories.
• Securities dematerialised have been listed on the stock exchanges where existing securities are listed.
• Certificates for dematerialisation were mutilated and cancelled; depositories' names substituted as registered owner within 15 days.